Kornimate/medical-research-clean huggingface dataset:
effect of rematazolam besylate, propofol, and sevoflurane perioperative sedation on incidence of emergence agitation and hemodynamics in patients undergoing laparoscopic abdominal surgery

Conditions: Emergence Agitation; Remimazolam Besylate; Perioperative Sedation; Laparoscopic Abdominal Surgery; Anesthesia, General

Summary: emergence agitation (ea) is a transient, self-limited, non-fluctuating state of psychomotor excitement, which closely revolves around the emergence of general anesthesia. uncontrolled ea during the recovery period increases the potential risk of injury to patients and medical staff, resulting in varying degrees of adverse consequences, such as elevated blood pressure, incision rupture, bleeding, cardio-cerebrovascular accidents and so on, leading to a great waste of resources. accumulating scientific evidence indicates that the incidence of ea is related to the use of perioperative sedative drugs. as a novel ultra-short-acting benzodiazepines drugs, remimazolam has been accepted for induction and maintenance of clinical anesthesia. compared to traditional benzodiazepines drugs, remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. this study aims to investigate whether perioperative sedation of remimazolam besylate, propofol, and sevoflurane have different effects on the incidence of emergence agitation and hemodynamics in patients undergoing laparoscopic abdominal surgery.


Eligibility criteria:
inclusion criteria: * 1 aged 18-65 years, sex was not limited; * 2 bmi 18-30kg/m2; * 3 patients were scheduled for elective laparoscopic abdominal surgery under general anesthesia, the operation time 2h\~4h; * 4 asa ⅰ-iii; exclusion criteria: * 1 relative contraindications to general anesthesia: patients with severe heart and lung disease, severe infection, uncontrolled hypertension, diabetes, and severe diabetic complications; * 2 abnormal renal and liver function: ast or alt≥2.5×uln, tbil≥1.5×uln, serum creatinine concentration (scc)≥1.5×uln; * 3 people with a history of mental illness or long-term use of psychotropic drugs (dementia, schizophrenia), chronic analgesic drug use, alcoholism, and cognitive impairment; * 4 any cardiovascular or cerebrovascular accidents occurred within 3 months, such as myocardial infarction, stroke, transient ischemic attack; * 5 female pregnant patients; * 6 patients undergoing hepatobiliary surgery; * 7 allergy to the experimental drug; * 8 unable to cooperate to complete the test, the patient or family member rejected the participant;

Keywords: emergence agitation remimazolam besylate propofol sevoflurane laparoscopic abdominal surgery perioperative sedation anesthesia, general
assessment of efficacy and safety of tegaserod treatment and placebo in women with dyspepsia

Conditions: Dyspepsia

Summary: this study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. tegaserod will be evaluated at 6mg twice daily and placebo.


Eligibility criteria:
inclusion criteria: * female, 18 years or older * self-reported presence of persistent or recurrent adverse digestive symptoms consistent with dyspepsia for at least 12 weeks, not necessarily consecutive, during the previous 12 months. exclusion criteria: * abnormal upper gi endoscopy findings such as esophageal, gastric erosions or ulcers and/or duodenal ulcers/erosions. * any of the following symptoms: heartburn, epigastric pain, nausea or vomiting. other protocol-defined inclusion/exclusion criteria may appl

Keywords: dyspepsia, gastrointestinal, tegaserod
changing eating behavior using cognitive training

Conditions: Obesity; Overweight; Weight Loss

Summary: obesity is a global health problem. new and more efficient interventions are needed to overcome this disease. this randomized clinical trial aims to evaluate the effectiveness of changing eating behavior using cognitive training. these types of interventions have the role of creating new routines (unconsciously processed), in terms of healthy eating behaviors.

this is a randomized clinical trial with three groups. participants will be found through social media announcements. the active interventions of cognitive training will be delivered at two groups: one group will receive through hypnosis and the other will receive through food inhibition training (a go no go task). the control group will receive a simple go no go task as an active placebo. the trial will be exclusively online and it consists of five sessions. participants will complete their tasks on four zoom sessions. cognitive, emotional and behavioral data will be taken at four times: before the intervention starts, in the middle (after two sessions), at the end and at two follow up moments: one month and six months after the trial ends.

Eligibility criteria:
inclusion criteria: * adults * persons who like high-calorie foods (self-report food preferences) * persons who have a medium to high score at the self-report daily snacking * bmi\>25 exclusion criteria: * enrolled in a weight loss program * under 18 years * health problems that can affect weight loss * persons with clinical problems such as diabetes, cardiovascular disease, mental problems, persons who take medicines that can affect weight loss

Keywords: obesity overweight weight loss hypnosis food inhibition training go no go task
triad - treatment of insomnia and depression

Conditions: Sleep Initiation and Maintenance Disorders; Depression

Summary: the aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (mdd) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

participants with major depressive disorder and insomnia who meet all study criteria will receive state-of-the-art antidepressant medications and one of two insomnia therapies. the specific therapy for insomnia will be determined by chance (like a flip of a coin), with an equal chance to receive either cognitive-behavioral therapy for insomnia or desensitization psychotherapy for insomnia. the study physician will select an initial antidepressant medication from a list of three possible medications . if that medication is not helpful, another medication may be tried after 8 weeks or in the event of severe side effects.

Eligibility criteria:
inclusion criteria: 1. meets criteria for major depressive disorder 2. between 18 and 75 years of age and adequately fluent in english 3. meets criteria for an insomnia disorder exclusion criteria: 1. women who are currently pregnant, breast-feeding, or not using a reliable birth control method. 2. people for whom the antidepressant medication(s) provided in the study is not indicated 3. people who have had minimum adequate trials of (or have not been able to tolerate) all three study medications. 4. people with uncontrolled medical conditions. 5. people with moderate or severe sleep disorders other than insomnia 6. individuals on a fixed night shift or rotating work schedule that requires a night shift. 7. patients with a current principal diagnosis of a psychiatric disorder that necessitates treatment that is not offered in the study.
pilot effectiveness trial of an act self-help workbook tailored specifically for prisons

Conditions: Anxiety; Depression; Depression, Anxiety; Anxiety Disorders

Summary: the goal of this research study is to adapt an act-self-help workbook to the prison setting and determine the feasibility acceptability, and effectiveness of this workbook. participants can expect to be in the study for 13 weeks.

the specific aims of the proposed study correspond directly to the three-step process. 1. in step 1 (specific aim #1), identify the necessary adaptations to the content, language, and format of an act-based self-help workbook through stakeholder input. 2. in step 2 (specific aim #2), refine the workbook and its delivery based on feedback from incarcerated individuals who complete the workbook. 3. in step 3 (specific aim #3), determine the feasibility, acceptability and preliminary effectiveness of the act self-help workbook in a prison setting. primary clinical outcome measure will be depression, secondary clinical outcome measure will be anxiety. for each participant assigned to a condition, a study team member will meet with them individually to provide them with a copy of the workbook. during this meeting, the study team member will inform the participant that they should complete one chapter per week. participants will complete a pre-treatment assessment prior to distribution of the workbook; a mid-treatment assessment four weeks after the distribution of the workbook; a post-treatment assessment #1 eight weeks after distribution of the workbook (when the workbook should be completed); focus group (after completion of workbook) and, a post-treatment assessment #2 twelve weeks after distribution of the workbook.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * reading level of 6th grade or higher determined by the wide range achievement test * moderate or severe anxiety and/or depression determined by the beck depression inventory-ii (bdi-ii) and beck anxiety inventory (bai) * no active self-harm or active suicidal intent * no scheduled transfer or release for at least three months * must be willing and able to participate, including having permission and ability to use study materials, such as paper and a writing utensil exclusion criteria: * unable to provide informed consent * active self-harm or suicidal intent * scheduled transfer or release within three months

Keywords: incarcerated
home blood pressure-guided antihypertensive intervention for elderly (hbp-guide) study

Conditions: Cardiovascular Disease; Vascular Disease; Hypertension

Summary: the purpose of this study is to determine whether blood pressure control by home blood pressure monitoring exerts beneficial cardioprotective effects rather than by clinic blood pressure monitoring in elderly patients.

home blood pressure (bp) measurement has been reported to be closely correlated with target organ damage and appears to be a prognostic indicator with respect to cardiovascular mortality and cardiovascular events. however, whether bp control by home bp monitoring exerts cardioprotective effects rather than by clinic bp monitoring in elderly patients remains unknown. in this study, a total of 500 elderly patients diagnosed with essential hypertension will be randomly divided into 2 groups; target bp level, home sbp \<135 mmhg and home dbp \<85 mmhg (home bp control group), clinic sbp \<140 mmhg and clinic dbp \<90 mmhg (clinic bp control group). olmesartan at doses of 20 mg/day will be administered and increased up to 40 mg, if antihypertensive effect is inadequate. study visits will be made bimonthly for at least 1 year. the antihypertensive and cardioprotective effects including systemic levels of c-reactive protein and inflammatory cytokines, and arterial stiffness will be compared between the two groups.

Eligibility criteria:
inclusion criteria: * outpatients aged over 65 years and less than 80 years * patients with a stable seated systolic blood pressure of ≥ 140 mmhg or diastolic blood pressure of ≥ 90 mmhg at two visits within 8 weeks * patients with a stable seated systolic blood pressure of ≥ 135 mmhg or diastolic blood pressure of ≥ 85 mmhg at home (home blood pressure is measured every morning within 1 h of waking, and defined as the mean of 3 days measurement within 8 weeks) exclusion criteria: * patients with secondary hypertension or malignant hypertension * patients with a stable seated systolic pressure of ≥ 180 mmhg or diastolic pressure of ≥ 110 mmhg * patients with renal dysfunction with a serum creatinine level of ≥ 2 mg/dl * patients with liver dysfunction * patients with a history of hypersensitivity to angiotensin ii receptor blockade * patients with a history of myocardial infarction within 6 months prior to enrolment in the study * patients who underwent coronary arterioplasty within 6 months prior to enrolment in the study or patients who will undergo coronary arterioplasty within 6 months after entry * patients with heart failure * patients with a history of cerebrovascular disorder * other patients who are judged to be inappropriate for the study by the investigator

Keywords: cardiovascular disease vascular disease hypertension home blood pressure measurement
the pk/pd study of single dose of shr3824 in healthy volunteers

Conditions: Type 2 Diabetes

Summary: shr3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. in this single-dose study the investigators evaluated the safety, tolerablity and pk/pd profiles of shr3824 in healthy subjects.


Eligibility criteria:
inclusion criteria: * chinese male and female subjects aged 18 to 45 years. * bmi:18 -25 kg/m2 . * healthy according to medical history, physical examination findings, 12-lead ecg findings, and clinical laboratory evaluations. exclusion criteria: * history of or current clinically significant medical illness as determined by the investigator. * history of clinically significant allergies, especially known hypersensitivity or intolerance to lactose. * pregnancy or breastfeeding . * significant acute or chronic medical illness, including renal impairment, or recent surgery. * donation of blood or plasma within the 4 weeks prior to the start of the study or acception of blood transfusion within 8 weeks.

Keywords: shr3824 type 2 diabetes mellitus sglt2
a graphene far-infrared intervention study of cognitive status in older adults

Conditions: Mild Cognitive Impairment (MCI); Subjective Cognitive Decrease (SCD); Alzheimer's Disease(AD); Depression/Anxiety Symptoms

Summary: this study is a 4-week group controlled trial to explore whether graphene far-infrared intervention can improve the cognitive status of older adults presenting with symptoms of subjective cognitive decline (scd), mild cognitive impairment (mci), or alzheimer's disease (ad), and is dedicated to enhancing the cognitive status of older adults and improving their mental health. participants were older adults who presented with cognitive problems. participants were divided into scd and mci/ad groups based on their cognitive level, and each group was further divided into a graphene far-infrared intervention group and a placebo control group. we also measured the depression and anxiety levels of the older adults and incidentally observed whether the graphene far-infrared intervention could have a positive impact on their mental health outcomes, which was not the focus of our study.


Eligibility criteria:
inclusion criteria: * age 55 years and above (age limit may be relaxed to not less than 45 years if there is a special desire to participate in the intervention) * no barriers to daily communication * individuals participating voluntarily exclusion criteria: * good cognitive functioning (scd score of 0) * subjective desire to withdraw * individuals who reported discomfort opting out during the experimental procedure

Keywords: graphene far infrared intervention (gfii) randomized controlled trial (rct) older adults subjective cognitive decrease (scd) mild cognitive impairment (mci) alzheimer&#39;s disease(ad)
comparison of the systematic versus the selective use of heparin for the prevention of radial artery occlusion

Conditions: Radial Artery Occlusion

Summary: randomized study comparing the systematic use of heparin (standard of care) against an elective use of heparin to prevent radial artery occlusion after a percutaneous catheterization using a dual-artery compression system.


Eligibility criteria:
inclusion criteria: * any patient referred for a diagnostic transradial catheterism exclusion criteria: * unable to understand study design or provide informed consent * unable to receive antiplatelet therapy with aspirina and/or clopidogrel-prasugrel and/or ticagrelor and intravenous anticoagulant derived from heparine or bivalirudine * local condition such as hematoma or pseudo-aneurims precluding radial or ulnar access. * presence of plethysmographic waveform with simultaneous radial and ulnar occlusive compression (due to colaterals or interouseous artery) precluding the evaluation of patent hemostasis.
the effect of wearing facial masks on skin parameters during the covid-19 pandemic

Conditions: Skin Condition; Skin Inflammation; Facial Skin Changes

Summary: the global coronavirus disease pandemic (covid-19) has led to an increased need to wear protective equipment such as wearing face masks and practicing hygiene measures such as more frequent use of antiseptics. these measures can lead to changes in the skin, the development of new inflammatory skin diseases or exacerbation of existing ones, with health professionals especially under the risk of developing these changes. changes in facial skin due to wearing masks have been observed in a number of studies, however, part of the study was based solely on subjects' self-assessment or clinical assessment, and only a small part on objective measurements of skin parameters. also, the impact of prolonged masks' use have not been investigated. the aim of these study was to investigate the effects of constant, long-term use of protective masks on facial skin.


Eligibility criteria:
inclusion criteria: * young, healthy volunteers who gave written informed consent - students of health related professions who wear facial mask for at least six hours a day durnig their internship/practice in health care institutions exclusion criteria: * skin disease, skin damage on measurement sites * use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial * use of emollients three days prior the inclusion in the trial * non-adherence to the trial protocol * exposure to artificial and excessive natural uv radiation * pregnancy and lactation * skin cancer * immunosuppression
kinesiotaping with and without combined chain exercises in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: knee osteoarthritis is a major public health issue because it causes chronic pain, reduces physical function and diminishes quality of life. aging of the population and increased global prevalence of obesity are anticipated to dramatically increase the prevalence of knee osteoarthritis. knee osteoarthritis is characterized by complex multifactorial joint pathology and is the most common form of joint disorder in the world. chronic knee osteoarthritis leads to marked weakening of the quadriceps femoris muscle, which is the extensor and stabilizer of the knee and atrophy of this muscle result knee pain and functional impairment. quadriceps muscle weakness and atrophy have been reported to contribute to functional impairment and pain in patients with knee osteoarthritis and quadriceps strengthening can be achieved through open kinetic chain exercises and close kinetic chain exercises. close kinetic chain exercises are modeled as, in which a movement in a joint simultaneously produces movements in other joints of the extremity. open kinetic chain exercises and close kinetic chain exercises form the combined chain exercises. kinesiotaping with these exercises to improve the patients suffering with knee osteoarthritis. the aim of this study will be to compare the effects of kinesiotaping as an adjunct to combined chain exercises compared with only kinesiotaping on pain, range of motion and quality of life in the management of individuals with knee osteoarthritis. this study will be randomized control trial. patients will be recruited into two groups by simple random assignment. non probability consecutive sampling technique will be used. data will be collected from patients of grade 2 knee osteoarthritis patients by using nprs for pain, goniometer for rom and sf-36 for quality of life will be used before and immediate after the treatment. those who will meet the inclusion criteria will be recruited. group 1 will be treated with kinesiotaping and combined chain exercises and the group 2 will be treated with only kinesiotaping on knee oa patients. total intervention will be given for four weeks for three sessions per week.the subject attended physical therapy and kinesiotaping will assess for pain, range of motion and quality of life at baseline and after 4 week of intervention. after collecting data from defined study setting, data will be entered and analyzed by using statistical package for the social sciences (spss) for windows software, version 25.


Eligibility criteria:
inclusion criteria: * male and female patients. * patients age between 40 years- 60years. * patients with grade ii knee osteoarthritis. exclusion criteria: * patients with allergic reaction to tape or any skin problems * patients with history of injection at the knee. * patients with surgical intervention at the knee

Keywords: knee osteoarthritis kinesiotaping combined chain exercises pain rom quality of life
treatment of the hypertensive leg ulcers by prf application

Conditions: Hypertensive Leg Ulcer

Summary: hypertensive leg ulcers are very painful and difficult to treat ulcers. their treatment is not well established. we want to study the efficacy of prf applications on the pains related to those ulcers. prf (platelet-rich fibrin) is an autologous fibrin clot, obtained extemporaneously from patient's blood, without any additive nor complex manipulation. it contains blood platelets and white blood cells, trapped in fibrin during clot formation. prf (platelet-rich fibrin) is form immediately after blood punction in a dry tube, that does not contain any anticoagulant. coagulation naturally occurs within few minutes, and tubes are placed in a centrifuge: red blood cells are separated from the fibrin clot thanks to difference of density, and blood platelets and white blood cells are trapped in the fibrin clot. the fibrin clot is then rapidly applicated on the ulcer surface for four days. our hypothesis is that platelet growth factors and cytokines, liberated during platelet activation, could help to treat hypertensive leg ulcers, that are caused by a vascular spasm.

2 to 8 prf (depending on the ulcer surface), applied on painful hypertensive leg ulcer, and covered by a dressing for 4 days. afterwards, dressings are made in a classical way. if needed (persistence of important pain), the prf application can be repeated after 7 days.

Eligibility criteria:
inclusion criteria: * hypertensive leg ulcer * important pain (\>= 5/10) exclusion criteria: * significant venous deficiency * significant arterial deficiency * other leg ulcers * any active diseases such as infection, neoplasia, auto-immune disease